Commercializing Innovation in China’s Multi-Layered Coverage Framework
A facilitated strategy session for global and China leadership teams
China’s pharmaceutical payment system is no longer a single-channel problem. As basic medical insurance and commercial health insurance increasingly interact, access decisions in China have become system-level, path-dependent, and portfolio-shaping.
This strategy session combines an essential strategic primer on China’s evolving access landscape with a facilitated discussion anchored in a selected priority asset, enabling leadership teams to move beyond execution debates and clarify the trade-offs that matter most.
Rather than prescribing a single “right” solution, the session is designed to surface risks, constraints, and sequencing choices—so China access decisions are deliberate, aligned, and defensible.
About the Speaker
Kelly Ke is the founder of bizi LLC and works at the intersection of health policy and commercial strategy, helping life sciences companies make informed China access decisions. Her co-authored Caixin article on the C-List roadmap has sparked impactful discussions across China’s policy and industry circles. She is a former award-winning Deloitte U.S. life sciences advisor and the founder and author of the NRDL+ Executive Debrief platform.
What Past Participants Are Saying
Strategy Session
“Thank you for the fruitful presentation yesterday. It provided us with a comprehensive overview of China’s multi-layer healthcare system, along with inspiring questions and takeaways that are valuable for our strategy development.”
— Head China Market Access, Top Specialty Pharma
C-List Masterclass
" It has been a delight to follow the C-List Masterclass. The timing is perfect, as it coincides with what may be a significant shift in how high-value medicines enter the Chinese market. The program allowed me to track developments in real time, with monitoring and analysis that highlighted both opportunities and remaining uncertainties. All in all, I would not have had it any other way—well done."
— Director Access Policy, Top 10 Pharma
"It’s difficult to conduct desk research on China’s reimbursement policy changes, so joining the C-List Masterclass was a great way to access clear, structured information in English. The panel sessions with China-based experts were particularly insightful and valuable."
— Head Global Market Access, Top Specialty Pharma
USC Lecture
"I went into this lecture knowing nothing about China’s healthcare system, but the discussion on the C-List and NRDL was truly enlightening from a future physician’s perspective." — Graduate Student, USC
"I really enjoyed how thorough and detailed the lecture was. Each slide was meaningful, deliberate, and tied to a clear learning goal. I learned so much in such a short time!" — Graduate Student, USC
“I learned a lot about China’s insurance system, which could really help me in the future as China continues to make progress. This session was truly insightful.” — Graduate Student, USC
“The case vignette was very helpful—it really pushed me to think strategically about the different factors involved in market access.” — Graduate Student, USC
"The lecture was very insightful, as the Chinese market is a completely new concept to me. Kelly was both knowledgeable and engaging in presenting the topic." — Graduate Student, USC
"I really liked the way Kelly explained the Chinese healthcare system and highlighted what could be improved in the future. She delivered a perfect lecture — I didn’t even expect that!” — Graduate Student, USC
Make Policy Work for Strategy
Turn complexity into clarity.
Turn policy shifts into strategic foresight.